RxDoctor Payments Data

Charmaine Scott, APRN

Psychiatric/Mental Health · Lauderhill, FLNPI 1780139782

Payments from drug & device makers

$2,819in general payments, 2019–2025

Across 134 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$667
  • Otsuka America Pharmaceutical, Inc.$439
  • AbbVie$351
  • Neurocrine Biosciences, Inc.$314
  • Alkermes, Inc.$247
  • Johnson & Johnson$236
  • plus $566 from 4 others

What the payments were for

  • Food & beverage$2,70996%
  • Education$1104%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,819 in reported general payments places this provider in the 80th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$7,863
Medicare patients
47
Services billed
148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole61$177,359
Invega SustennaPaliperidone Palmitate58$157,817
Austedo XrDeutetrabenazine11$69,533
AustedoDeutetrabenazine12$48,137
AristadaAripiprazole Lauroxil14$47,316
VraylarCariprazine Hcl18$29,840
Lurasidone Hcl39$19,018
UzedyRisperidone12$15,899
Aripiprazole128$11,224
TrintellixVortioxetine Hydrobromide11$9,605
Clozapine72$5,522
Haloperidol Decanoate89$5,322
Quetiapine Fumarate237$4,368
Trazodone Hcl308$3,895
Benztropine Mesylate354$3,551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$439$177,35961 claims
Johnson & JohnsonInvega Sustenna$236$157,81758 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Uzedy$667$133,57035 claims
Alkermes, Inc.Aristada$247$47,31614 claims
AbbVieVraylar$351$29,84018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Lauderhill

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →